Pharma Partnerships Strateos has demonstrated credible pharma collaboration with Lilly Life Sciences Studio and investor interest from the sector, signaling a path to enterprise deals. This presents opportunities to scale Automation-as-a-Service with large pharma and CRO networks, offering multi site deployments, strong SLAs, data security, and seamless integration with existing enterprise systems.

Small Molecule Focus The expansion to an idea-to-data solution for small molecule discovery creates a compelling hook for medicinal chemistry teams seeking rapid, reproducible experiments and accelerated iteration. Propose bundled offerings that pair remote lab execution with in silico screening and data analytics to shorten hit to lead cycles.

Data Driven Growth Strateos software driven and data centric approach enables upsell of advanced analytics, dashboards, data pipelines, and tight LIMS/ELN integration, helping customers turn experimental data into actionable insights and faster decision making.

Scale Ready Strong funding rounds and leadership appointments signal growth readiness, pointing to Enterprise R&D centers and global pharma networks as opportunities for long term value contracts built on scalable, compliant, and secure remote lab infrastructure.

Competitive Edge As a pioneer in remote access laboratories, Strateos can leverage its competitive edge in a market trending toward automation and remote experimentation to pursue cross disease collaborations, contract research arrangements, and strategic partnerships that broaden platform adoption.